Serina Therapeutics is developing proprietary drugs to treat neurological diseases, cancer and pain. In addition, we are partnering the POZ™ platform to develop pharmaceuticals for other companies – which include antibody drug conjugates, proteins and small molecules. The POZ drug conjugate platform is broad, customizable and versatile, and can be dosed via IV,   SC or IM routes.



Parkinson’s disease (PD) is a chronic, progressive neurological disorder that results from a deficiency of dopamine in a specialized region of the brain known as the substantia nigra. As many as ten million people worldwide may be affected by the disease. Current treatments for PD often need to be individually titrated in patients, with many patients taking their drugs several times a day. None of these therapies deliver the drug continuously to replace the deficiency of dopamine in the brain. As a result, many of these drugs are complicated by “wearing off” and involuntary motor fluctuation known as dyskinesia.

At Serina, we intend to create a paradigm shift in how PD is treated. SER-214 is a once-weekly subcutaneous injection that has completed Phase Ia in Parkinson’s patients. SER-214 is safe, very well-tolerated and can be delivered in the convenience of your own home – you don’t need a doctor or nurse to deliver it.

Patients with advancing disease frequently develop “off” time – their existing medications simply do not allow them to perform even routine activities. These periods dramatically reduce the quality of life for these patients. At present there are two surgical options for these patients – deep brain stimulation (DBS) and an intestinal catheter delivery system for L-DOPA known as Duopa (AbbVie).

Serina has a new approach to treat “off” time called SER-252 (POZ-apomorphine). Apomorphine is the “holy grail” of dopamine therapy in advanced disease – capable of reversing “off” periods within minutes. But the current formulations are confounded by severe skin reactions, and it must be delivered as a continuous subcutaneous infusion each day. This often requires a health care provider to set it up. We think there is a better way – SER-252 may be delivered as a single injection once a week, just like SER-214. No adverse skin reactions, no need for a doctor or nurse to administer it. We believe it may be possible in the future to get patients with advancing disease off L-DOPA entirely.

SER-214 for early Parkinson’s patients, and SER-252 for more advanced patients, will create a paradigm shift in how patients with Parkinson’s disease may be treated.

Learn More | SER-214 Fact Sheet



Many drugs, for example those used to treat neurological disorders like Parkinson’s disease, pain and cancer, have narrow therapeutic ranges in which they can work safely and efficaciously. They are often dosed more frequently – resulting in large and frequent fluctuations in drug exposure. Such drugs may have to be monitored and the dose adjusted with greater frequency, and on an individual basis. These fluctuations present clinical, compliance and quality of life challenges for many patients. The POZ™ technology provides greater control in drug loading, and the rate of release of attached drugs can often be more precisely controlled. Thus, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood.


Increasing DAR Using Antibody Drug Conjugates

Serina has shown that the POZ™ polymers can be attached to antibodies, and when those polymers are “pay-loaded” with large amounts of cytotoxic agents they can dramatically increase the drug antibody ratio (DAR). We and our partners believe that this will be particularly important when the antigen for the ADC has low cell surface expression.

For an illustration of how this is accomplished, click here.

Targeting POZ™ to Cell Surface Receptors by Small Molecules

The POZ™ technology is uniquely suited for targeting a “payload” of toxin to specific receptors that are overexpressed on the surface of cancer cells. An example of this is the high affinity folate receptor alpha, which is expressed only on the surface of certain types of cancers.

Both of these approaches may prove to be highly advantageous for the treatment of cancer, but could also be applied to treat other diseases where the release of the attached drug needs to be site specific.